Entera Bio Ltd. filings document a Nasdaq-listed Israeli clinical-stage biopharmaceutical company developing oral peptide and protein replacement therapies. Its recent Form 8-K disclosures cover financial results, Regulation FD updates, EB613 regulatory and clinical-development communications, and business updates across oral peptide programs.
The filing record also documents material agreements and capital structure matters, including collaboration and license arrangements with OPKO, a private placement involving ordinary shares, pre-funded warrants and ordinary share warrants, and governance disclosures related to board appointments. These filings frame ENTX's operating updates, securities structure, partnership obligations and public-company governance.
Entera Bio Ltd. appointed Juan Camilo Arjona Ferreira, M.D., as a Class II director, effective December 1, 2026; he also joins the compensation committee that day. His term runs through the 2027 Annual Meeting of Shareholders and until a successor is elected and qualified, subject to earlier death, resignation, retirement, disqualification or removal. The board determined that he is independent under applicable SEC and Nasdaq Stock Market rules.
Dr. Arjona Ferreira currently serves as Head of Research & Development and Chief Medical Officer at Organon & Co. and has more than 20 years of global clinical development experience. Haya Taitel is stepping down as a director, effective December 1, 2026; Entera stated her departure was not the result of a disagreement with the company. Dr. Arjona Ferreira will participate in Entera’s standard non-employee director compensation arrangements, including annual cash payments for Board and applicable committee service and annual equity grants under the 2018 Equity Incentive Plan.
Entera Bio Ltd. is asking shareholders to vote on eight proposals at its November 24, 2026 special meeting. They include increasing the 2018 Equity Incentive Plan by 13,937,915 ordinary shares; approving one-time equity grants to CEO Miranda Toledano, CFO Dana Yaacov-Garbeli, COO Hillel Galitzer and Chief of Research and Development Gregory Burshtein; amending the compensation policy and non-executive director compensation; and extending the post-termination exercise period for share options granted or to be granted to officers and directors. The board unanimously recommends voting FOR all eight proposals.
Proposals One through Five are presented in connection with the July 2026 private placement, whose purchasers agreed to vote shares they beneficially hold in favor of those proposals. Entera says the placement raised approximately $275 million in gross proceeds and expects it to fully fund the EB613 Phase 3 registrational program and extend its cash runway into 2030. Shareholders of record on October 1, 2026 may vote; Entera reported 173,922,428 ordinary shares outstanding on that date. As of September 14, 2026, 3,087,230 shares remained available under the 2018 Plan.
Entera Bio Ltd. appointed biopharmaceutical executive Laura Hamill as a Class I director, effective December 1, 2026; she will also join the audit and corporate governance and nomination committees on that date. Director Yonatan Malca notified the board that he will step down effective December 1, 2026, and Entera said his departure was not the result of a disagreement over its operations, policies or practices. The board determined Hamill is independent under applicable SEC and Nasdaq rules. She will participate in Entera’s standard non-employee director compensation arrangements, including annual cash payments for board and applicable committee service and annual equity grants under the 2018 Equity Incentive Plan. Hamill brings more than 35 years of commercial leadership experience, including most recently as Executive Vice President, Worldwide Commercial Operations at Gilead and senior roles at Amgen. She currently serves on the boards of Jazz Pharmaceuticals, BB Biotech and Fate Therapeutics.
Entera Bio Ltd. is asking shareholders to vote on eight proposals at its November 24, 2026 special meeting. Holders of record on October 1, 2026 may vote, and the Board recommends FOR all eight. Proposal One would increase by 13,937,915 Ordinary Shares the number issuable under the 2018 Equity Incentive Plan. Proposals Two through Five seek one-time equity grants to Chief Executive Officer and Director Miranda Toledano, Chief Financial Officer Dana Yaacov-Garbeli, Chief Operating Officer Hillel Galitzer and Chief of Research and Development Gregory Burshtein. The remaining proposals address an amended compensation policy, non-executive director compensation and the post-termination exercise period for officer and director options.
The proposals follow a private placement that closed July 28, 2026, for approximately $275.0 million in gross proceeds. Purchasers agreed to vote shares they beneficially hold in favor of Proposals One through Five, but are not obligated to support Proposals Six through Eight. Entera says it expects the financing to fully fund EB613’s Phase 3 registrational program and extend its cash runway into 2030. If approved, the amended compensation policy is intended to be effective for three years, or longer as permitted under Israeli law.
Entera Bio Ltd. (ENTX) is registering for resale, under a Form S-3 shelf, up to 134,803,910 ordinary shares offered by existing selling shareholders. This total consists of 122,961,215 ordinary shares already issued and up to 11,842,695 ordinary shares issuable upon exercise of Pre-Funded Warrants issued in a July 28, 2026 private placement.
The selling shareholders may sell shares from time to time using various methods, and Entera will not receive any proceeds from these resales, though it will cover registration expenses. Entera’s ordinary shares trade on Nasdaq under the symbol “ENTX”; the closing price was $3.08 on August 27, 2026.
The company highlights significant political, security and economic risks in the Middle East, as its principal research facilities and many key personnel are in Israel. Its auditors have included an explanatory paragraph regarding Entera’s ability to continue as a going concern in the 2025 financial statements, and investors are directed to detailed risk factors incorporated by reference.
Entera Bio Ltd. (ENTX) has filed a shelf resale registration covering up to 134,803,910 ordinary shares that may be offered from time to time by existing holders from a July 28, 2026 private placement. The registered shares consist of 122,961,215 ordinary shares and up to 11,842,695 ordinary shares issuable upon exercise of Pre-Funded Warrants. Entera states it will not receive any proceeds from sales of these shares by the selling shareholders, though it will bear the registration fees and related offering expenses.
The ordinary shares trade on Nasdaq under the symbol ENTX, and the closing price on August 20, 2026 was $3.22 per share. As context, Entera reports 173,834,271 ordinary shares outstanding as of August 17, 2026 and authorized capital of 350,000,000 ordinary shares. The filing emphasizes significant risk factors, including extensive recent and ongoing security, political and economic instability in the Middle East that could adversely affect its Israel-based operations. The company’s independent auditor’s report for the year ended December 31, 2025 includes an explanatory paragraph regarding Entera’s ability to continue as a going concern.
Entera Bio Ltd. (ENTX) reported an initial statement of beneficial ownership for Riccardo Paolo Camisasca, who serves as Chief Medical Officer. The Form 3 lists him as an officer but does not report any equity transactions, holdings tables, or derivative positions at this time.
Entera Bio Ltd. appointed Riccardo Paolo Camisasca, M.D. as Chief Medical Officer effective August 18, 2026. He brings more than 30 years of experience in clinical development, medical affairs, regulatory strategy and R&D leadership, including serving as Global Head of R&D at Sumitomo Pharma Switzerland and prior senior roles at Bial, Syneos Health, Takeda and Novartis.
The appointment is positioned to support late-stage development of Entera’s lead oral peptide candidate EB613, an oral PTH(1-34) tablet for osteoporosis. A 6‑month, 161‑patient, placebo-controlled Phase 2 study of EB613 met primary biomarker and secondary BMD endpoints without significant safety concerns, and the company is planning Phase 3 initiation.
Entera Bio Ltd., an Israel-incorporated biotechnology company, reported a completed exempt securities offering under Regulation D Rule 506(b). The company sold $274,999,976 of securities, consisting of an aggregate of 122,961,215 Ordinary Shares and 11,842,695 pre-funded warrants, with no remaining amount to be sold. The first sale occurred on July 28, 2026. The offering involved equity, options/warrants, and the underlying ordinary shares, with multiple investment banks identified for sales compensation and no finders’ fees reported.